Rosacea is a chronic facial inflammatory condition characterized by persistent erythema, flushing, and papulopustular lesions. Though rosacea has been recognized for centuries, its pathogenesis remains incompletely understood—yet recent microbiological discoveries have revealed that rosacea involves complex interactions between Demodex mites, dysbiotic bacteria, and aberrant immune responses.
Demodex folliculorum and Demodex brevis are small mites (approximately 0.3-0.4 mm in length) that normally colonize human skin, particularly hair follicles and sebaceous glands. Surveys of healthy individuals find Demodex on approximately 80% of people, with populations typically remaining asymptomatic. However, individuals with rosacea have dramatically elevated Demodex populations—15-fold higher densities than non-rosacea controls in some studies. This observation has led to the hypothesis that Demodex overgrowth drives rosacea pathogenesis, though causation remains incompletely established.
The mechanism by which Demodex might trigger rosacea involves both direct mite effects and immune responses to mite antigens. Demodex mites have symbiotic Bacillus oleronius bacteria within their bodies. When Demodex die (which occurs constantly as individual mites have short lifespans), these bacteria are released into hair follicles where they trigger innate immune responses. Specifically, B. oleronius antigens trigger TLR2 and TLR4 signaling in dendritic cells and keratinocytes, producing TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines. This chronic antigenic stimulation from Demodex-associated bacteria might explain rosacea's persistent inflammatory nature.
A key feature of rosacea skin is cathelicidin LL-37 overexpression. Cathelicidins are antimicrobial peptides produced by skin cells and immune cells, normally serving protective functions against pathogenic bacteria. However, in rosacea, LL-37 is constitutively elevated and aberrantly processed by two serine proteases (KLK5 and KLK7) produced by keratinocytes. This aberrant processing generates shorter LL-37 fragments with different immunological properties—these fragments are more pro-inflammatory, triggering increased mast cell degranulation and increased vascular permeability. This explains rosacea's characteristic flushing and persistent erythema: the combination of elevated LL-37 and aberrant processing creates a pro-inflammatory microenvironment driven by antimicrobial peptide dysregulation.
Gut dysbiosis and systemic inflammation may contribute to rosacea pathogenesis. Studies document elevated rates of small intestinal bacterial overgrowth (SIBO) in rosacea patients—approximately 46% of rosacea patients versus 5% of healthy controls. SIBO would increase intestinal permeability and allow translocation of bacterial lipopolysaccharide (LPS), triggering systemic inflammation. Additionally, dysbiotic microbiota patterns would reduce short-chain fatty acid production and butyrate-driven regulatory T cell generation, potentially impairing systemic immune tolerance and allowing enhanced inflammatory responses to Demodex and Bacillus antigens.
Helicobacter pylori infection associates with rosacea in some populations, particularly in Asia, though this association is less consistent in Western populations. H. pylori and rosacea share immune dysregulation patterns—elevated TNF-α and IL-6 in both conditions. Whether H. pylori directly drives rosacea or whether the association reflects shared risk factors remains unclear.
Treatment approaches target multiple mechanisms of rosacea pathogenesis. Antimicrobial strategies using ivermectin (a broad-spectrum antiparasitic) target Demodex mites, reducing mite populations and Bacillus-associated inflammation. Topical antibiotics (metronidazole, sulfacetamide) have anti-inflammatory properties beyond their antimicrobial effects—they suppress TNF-α and IL-1β production independent of bacterial killing. Oral antibiotics (doxycycline at sub-antimicrobial doses) provide anti-inflammatory effects through multiple mechanisms including TNF-α suppression and direct effects on keratinocyte LL-37 processing.
Anti-inflammatory approaches target downstream inflammation rather than microbiological triggers. Topical corticosteroids reduce inflammation, though chronic use becomes problematic. Calcineurin inhibitors (tacrolimus, pimecrolimus) suppress immune activation. Azelaic acid, commonly used in rosacea treatment, has antimicrobial effects against Bacillus and Demodex while also suppressing LL-37 overexpression and keratinocyte activation.
Emerging approaches targeting TLR signaling (TLR2/TLR4 antagonists) or LL-37 processing may provide more targeted interventions. Probiotics and dietary modifications targeting SIBO might address potential gut contributions. Understanding rosacea as a multifactorial condition involving Demodex mites, dysbiotic bacteria, aberrant antimicrobial peptide processing, and systemic inflammation has shifted treatment paradigms from simple antimicrobial approaches to more nuanced strategies addressing underlying pathophysiology.